Aytu BioPharma (STU:AY20) Debt-to-Equity : 0.56 (As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Aytu BioPharma Debt-to-Equity?

Aytu BioPharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €5.52 Mil. Aytu BioPharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was €9.40 Mil. Aytu BioPharma's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €26.87 Mil. Aytu BioPharma's debt to equity for the quarter that ended in Sep. 2024 was 0.56.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Aytu BioPharma's Debt-to-Equity or its related term are showing as below:

STU:AY20' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.73 Med: 0.29 Max: 0.61
Current: 0.56

During the past 13 years, the highest Debt-to-Equity Ratio of Aytu BioPharma was 0.61. The lowest was -0.73. And the median was 0.29.

STU:AY20's Debt-to-Equity is ranked worse than
71.79% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs STU:AY20: 0.56

Aytu BioPharma Debt-to-Equity Historical Data

The historical data trend for Aytu BioPharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Debt-to-Equity Chart

Aytu BioPharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Debt-to-Equity

Get a 7-Day Free Trial

0.02

0.18

0.41

0.42

0.55

Aytu BioPharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.50	0.49	0.54	0.55	0.56

Competitive Comparison of Aytu BioPharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Aytu BioPharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aytu BioPharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aytu BioPharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Aytu BioPharma's Debt-to-Equity falls into.

Aytu BioPharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Aytu BioPharma's Debt to Equity Ratio for the fiscal year that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.95	+	10.105)	/	25.748
	=	0.55

Aytu BioPharma's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.52	+	9.397)	/	26.873
	=	0.56

Aytu BioPharma (STU:AY20) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Aytu BioPharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Aytu BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (STU:AY20) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AYTU:USA 0A8M:UK

Address

7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237

Website

https://www.aytubio.com

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines